PT980252E - Terapias para insuficiencia renal aguda - Google Patents
Terapias para insuficiencia renal agudaInfo
- Publication number
- PT980252E PT980252E PT98919715T PT98919715T PT980252E PT 980252 E PT980252 E PT 980252E PT 98919715 T PT98919715 T PT 98919715T PT 98919715 T PT98919715 T PT 98919715T PT 980252 E PT980252 E PT 980252E
- Authority
- PT
- Portugal
- Prior art keywords
- acute renal
- therapies
- renal insufficiency
- risk
- treatment
- Prior art date
Links
- 208000009304 Acute Kidney Injury Diseases 0.000 title abstract 2
- 208000033626 Renal failure acute Diseases 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 abstract 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 abstract 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 201000011040 acute kidney failure Diseases 0.000 abstract 1
- 208000012998 acute renal failure Diseases 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 229940112869 bone morphogenetic protein Drugs 0.000 abstract 1
- 230000005779 cell damage Effects 0.000 abstract 1
- 208000037887 cell injury Diseases 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 210000000440 neutrophil Anatomy 0.000 abstract 1
- 230000002188 osteogenic effect Effects 0.000 abstract 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract 1
- 230000000451 tissue damage Effects 0.000 abstract 1
- 231100000827 tissue damage Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4561997P | 1997-05-05 | 1997-05-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT980252E true PT980252E (pt) | 2005-01-31 |
Family
ID=21938961
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT98919715T PT980252E (pt) | 1997-05-05 | 1998-05-05 | Terapias para insuficiencia renal aguda |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20100105621A1 (https=) |
| EP (1) | EP0980252B1 (https=) |
| JP (2) | JP5033276B2 (https=) |
| AT (1) | ATE278414T1 (https=) |
| AU (1) | AU743510B2 (https=) |
| CA (1) | CA2289123A1 (https=) |
| DE (1) | DE69826854T2 (https=) |
| DK (1) | DK0980252T3 (https=) |
| ES (1) | ES2226125T3 (https=) |
| PT (1) | PT980252E (https=) |
| WO (1) | WO1998050060A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7612046B2 (en) | 2000-01-31 | 2009-11-03 | Uwe Waldemar Rothenpieler | Method for treating kidney disorders |
| ES2351957T3 (es) * | 2000-01-31 | 2011-02-14 | Uwe Waldemar Rothenpieler | Pax2 para tratar trastornos del riñón. |
| EP1407770B1 (en) * | 2001-06-26 | 2013-06-05 | Takeda Pharmaceutical Company Limited | Tgf-beta superfamily production/secretion promoter |
| US20050272649A1 (en) * | 2002-08-28 | 2005-12-08 | Hruska Keith A | Conjoint administration of morphogens and ACE inhibitors in treatment of chronic renal failure |
| RU2282899C2 (ru) * | 2004-01-09 | 2006-08-27 | ГОУ ВПО Омская Государственная Медицинская Академия | Способ моделирования инфекции мочевой системы |
| EP3147296A1 (en) * | 2005-11-14 | 2017-03-29 | Merial, Inc. | Gene therapy for renal failure |
| US8025881B2 (en) | 2006-07-21 | 2011-09-27 | Chugai Seiyaku Kabushiki Kaisha | BMP antibodies and methods of treating kidney disease using the same |
| US8979797B2 (en) * | 2010-12-16 | 2015-03-17 | Ams Research Corporation | High pressure delivery system and method for treating pelvic disorder using large molecule therapeutics |
| US9169308B2 (en) | 2013-01-25 | 2015-10-27 | Warsaw Orthopedic, Inc. | Methods and compositions of human recombinant growth and differentiation factor-5 (rhGDF-5) isolated from inclusion bodies |
| US8956829B2 (en) | 2013-01-25 | 2015-02-17 | Warsaw Orthopedic, Inc. | Human recombinant growth and differentiaton factor-5 (rhGDF-5) |
| US8945872B2 (en) | 2013-01-25 | 2015-02-03 | Warsaw Orthopedic, Inc. | Methods of purifying human recombinant growth and differentiation factor-5 (rhGDF-5) protein |
| US9051389B2 (en) | 2013-01-25 | 2015-06-09 | Warsaw Orthopedic, Inc. | Expression conditions and methods of human recombinant growth and differentiation factor-5 (rhGDF-5) |
| US9359417B2 (en) | 2013-01-25 | 2016-06-07 | Warsaw Orthopedic, Inc. | Cell cultures and methods of human recombinant growth and differentiaton factor-5 (rhGDF-5) |
| KR101870246B1 (ko) * | 2014-02-07 | 2018-06-22 | 토루 미야자키 | 신질환의 예방 또는 치료제 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1156741B (it) | 1978-05-15 | 1987-02-04 | Sigma Tau Ind Farmaceuti | Applicazione terapeutica della carnitina e di alcuni derivati acilati della carnitina nell'emodialisi |
| US4342828A (en) | 1979-07-20 | 1982-08-03 | Morinaga Milk Industry Co., Ltd. | Method for producing substance capable of stimulating differentiation and proliferation of human granulopoietic stem cells |
| US4627839A (en) * | 1985-11-21 | 1986-12-09 | American Hospital Supply Corporation | Patient controlled analgesia conversion |
| IL83003A (en) | 1986-07-01 | 1995-07-31 | Genetics Inst | Osteoinductive factors |
| US5013649A (en) * | 1986-07-01 | 1991-05-07 | Genetics Institute, Inc. | DNA sequences encoding osteoinductive products |
| US5011691A (en) * | 1988-08-15 | 1991-04-30 | Stryker Corporation | Osteogenic devices |
| US5266683A (en) * | 1988-04-08 | 1993-11-30 | Stryker Corporation | Osteogenic proteins |
| US5045452A (en) * | 1988-09-02 | 1991-09-03 | Brigham And Women's Hospital | Method for evaluating nephrotoxicity |
| DE69031939T2 (de) | 1989-03-28 | 1998-09-10 | Genetics Institute, Inc., Cambridge, Mass. | Osteoinduktive zusammensetzungen |
| JPH06500991A (ja) | 1990-05-16 | 1994-01-27 | ジェネティックス・インスティテュート・インコーポレイテッド | 骨および軟骨誘導蛋白質 |
| JPH0426624A (ja) | 1990-05-18 | 1992-01-29 | Tsumura & Co | 慢性腎不全改善剤 |
| JPH05509086A (ja) | 1990-06-22 | 1993-12-16 | イー・アイ・デュポン・ドゥ・ヌムール・アンド・カンパニー | イミダゾールアンジオテンシン―２受容体拮抗薬による慢性腎不全の治療 |
| US6077823A (en) * | 1991-03-11 | 2000-06-20 | Creative Biomolecules, Inc. | Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury |
| US5849686A (en) * | 1991-03-11 | 1998-12-15 | Creative Biomolecules, Inc. | Morphogen-induced liver regeneration |
| US6194376B1 (en) * | 1991-03-11 | 2001-02-27 | Creative Biomolecules, Inc. | Method for modulating inflammatory response comprising administering morphogen |
| WO1992015323A1 (en) | 1991-03-11 | 1992-09-17 | Creative Biomolecules, Inc. | Protein-induced morphogenesis |
| CA2363965C (en) * | 1991-03-11 | 2010-05-18 | Curis, Inc. | Protein-induced morphogenesis |
| US7056882B2 (en) * | 1991-03-11 | 2006-06-06 | Curis, Inc. | Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases |
| US6287816B1 (en) | 1991-06-25 | 2001-09-11 | Genetics Institute, Inc. | BMP-9 compositions |
| DE69233559T2 (de) * | 1991-08-30 | 2006-08-31 | Curis, Inc., Cambridge | Osteogenische proteine in der behandlung von metabolischen knochenkrankheiten |
| EP0601129B1 (en) | 1991-08-30 | 2000-11-15 | Creative Biomolecules, Inc. | Morphogenic protein screening method |
| ATE192931T1 (de) * | 1991-08-30 | 2000-06-15 | Creative Biomolecules Inc | Morphogen-induzierte modulation von entzündlichen antworten |
| US6120760A (en) * | 1992-02-12 | 2000-09-19 | Biopharm Gesellschaft Zur Biotechnologischen Entwicklung | Growth/differentiation factors of the TGF-β family |
| JPH07509720A (ja) | 1992-07-31 | 1995-10-26 | クリエイティブ バイオモレキュルズ，インコーポレイテッド | モルフォゲン強化栄養組成物 |
| EP0653942B2 (en) * | 1992-07-31 | 2007-03-07 | Curis, Inc. | Morphogen-induced nerve regeneration and repair |
| ATE287949T1 (de) | 1992-07-31 | 2005-02-15 | Stryker Corp | Löslicher komplex morphogener proteine und zusammensetzungen davon |
| ES2114073T3 (es) | 1992-09-16 | 1998-05-16 | Creative Biomolecules Inc | Regeneracion del higado inducida por morfogenes. |
| JPH08503198A (ja) | 1992-11-03 | 1996-04-09 | クリエイティブ バイオモレキュルズ，インコーポレイテッド | Ｏｐ−３誘導形態形成 |
| JPH08510446A (ja) | 1993-03-04 | 1996-11-05 | クリエイティブ バイオモレキュルズ，インコーポレイテッド | 組換え骨形成タンパク質を生成するための方法および組成物 |
| US5631159A (en) | 1993-09-22 | 1997-05-20 | Creative Biomolecules, Inc. | Lipid-modified serum free media |
| US5585237A (en) | 1993-10-25 | 1996-12-17 | Creative Biomolecules, Inc. | Methods and compositions for high protein production from recombinant DNA |
| JPH09509141A (ja) * | 1993-11-15 | 1997-09-16 | セルトリックス ファーマシューティカルズ，インコーポレイテッド | Ｉｇｆ‐ｉおよびｉｇｆｂｐ‐３を投与することによる腎臓疾患処置の方法 |
| US5525621A (en) * | 1994-05-20 | 1996-06-11 | Cytos Pharmaceuticals Llc | Imidazole derivatives as protective agents in reperfusion injury and severe inflammatory responses |
| US5714511A (en) * | 1995-07-31 | 1998-02-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Selective prevention of organ injury in sepsis and shock using selection release of nitric oxide in vulnerable organs |
| KR20000064752A (ko) * | 1996-03-22 | 2000-11-06 | 더 제네랄 호스피탈 코포레이션 | 중추신경계허혈또는외상의발현후폴리펩티드성장인자를투여하는방법 |
| US5820589A (en) * | 1996-04-30 | 1998-10-13 | Medtronic, Inc. | Implantable non-invasive rate-adjustable pump |
| US6498142B1 (en) * | 1996-05-06 | 2002-12-24 | Curis, Inc. | Morphogen treatment for chronic renal failure |
| US5879908A (en) * | 1997-04-30 | 1999-03-09 | Smithkline Beecham Corporation | CRFG-1a, a target and marker for chronic renal failure |
| US7147839B2 (en) | 1998-05-29 | 2006-12-12 | Curis, Inc. | Methods for evaluating tissue morphogenesis and activity |
-
1998
- 1998-05-05 WO PCT/US1998/003197 patent/WO1998050060A1/en not_active Ceased
- 1998-05-05 AT AT98919715T patent/ATE278414T1/de active
- 1998-05-05 PT PT98919715T patent/PT980252E/pt unknown
- 1998-05-05 AU AU72443/98A patent/AU743510B2/en not_active Ceased
- 1998-05-05 CA CA002289123A patent/CA2289123A1/en not_active Abandoned
- 1998-05-05 JP JP54804898A patent/JP5033276B2/ja not_active Expired - Fee Related
- 1998-05-05 DE DE69826854T patent/DE69826854T2/de not_active Expired - Lifetime
- 1998-05-05 DK DK98919715T patent/DK0980252T3/da active
- 1998-05-05 ES ES98919715T patent/ES2226125T3/es not_active Expired - Lifetime
- 1998-05-05 EP EP98919715A patent/EP0980252B1/en not_active Expired - Lifetime
-
2009
- 2009-08-11 US US12/583,013 patent/US20100105621A1/en not_active Abandoned
- 2009-09-11 JP JP2009211128A patent/JP2009286802A/ja not_active Withdrawn
-
2011
- 2011-04-04 US US13/079,161 patent/US8748378B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2289123A1 (en) | 1998-11-12 |
| AU743510B2 (en) | 2002-01-24 |
| JP5033276B2 (ja) | 2012-09-26 |
| DK0980252T3 (da) | 2005-01-31 |
| DE69826854T2 (de) | 2006-02-02 |
| ATE278414T1 (de) | 2004-10-15 |
| JP2009286802A (ja) | 2009-12-10 |
| EP0980252A1 (en) | 2000-02-23 |
| EP0980252B1 (en) | 2004-10-06 |
| JP2001523264A (ja) | 2001-11-20 |
| ES2226125T3 (es) | 2005-03-16 |
| WO1998050060A1 (en) | 1998-11-12 |
| US8748378B2 (en) | 2014-06-10 |
| DE69826854D1 (de) | 2004-11-11 |
| US20100105621A1 (en) | 2010-04-29 |
| US20110257093A1 (en) | 2011-10-20 |
| AU7244398A (en) | 1998-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT910400E (pt) | Terapias para insuficiencia renal cronica | |
| PT980252E (pt) | Terapias para insuficiencia renal aguda | |
| Ahmed et al. | Fibrin glues in combination with mesenchymal stem cells to develop a tissue-engineered cartilage substitute | |
| Mulder et al. | Treatment of nonhealing diabetic foot ulcers with a platelet‐derived growth factor gene‐activated matrix (GAM501): Results of a Phase 1/2 trial | |
| Gilbertie et al. | Pooled platelet-rich plasma lysate therapy increases synoviocyte proliferation and hyaluronic acid production while protecting chondrocytes from synoviocyte-derived inflammatory mediators | |
| ES2147752T3 (es) | Descontaminacion de plaquetas con 8-metoxipsoraleno. | |
| Dawson et al. | The periosteal requirement and temporal dynamics of BMP2‐induced middle phalanx regeneration in the adult mouse | |
| TR199802421T2 (xx) | Doku yenilenmesini d�zenleyen maddeler. | |
| DK1238658T3 (da) | Understöttet afgivelse af et aktivt middel under anvendelse af et implanterbart system | |
| BR9707325A (pt) | Processo para o tratamento de um paciente afetado com uma doença mediada por il-1, composição farmacéutica e uso da mesma | |
| DK0564502T3 (da) | Vævsforseglingsmiddel og vækstfaktorholdige præparater, der fremmer accelereret sårheling | |
| NO20001754L (no) | Prostaglandinagonister og anvendelse derav for behandling av benforstyrrelser | |
| ES2069750T3 (es) | Metodos y composiciones para curar huesos. | |
| SE8501050D0 (sv) | Biologically active fragments of human antihemophilic factor and method for preparation thereof | |
| ATE273031T1 (de) | Aminobiguanide und ihre verwendung zur desinfektion von kontaktlinsen und konservierung von pharmazeutischen zubereitungen | |
| DE69719754D1 (de) | Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung | |
| ATE433461T1 (de) | Rana pipiens proteine und deren verwendung in der behandlung von tumoren | |
| RU95106680A (ru) | Бициклические ароматические соединения и содержащие их фармацевтические и косметические композиции | |
| ATE361756T1 (de) | Insulinartiger-wachstumsfaktorbindungsprotein-4 protease | |
| DE69721484D1 (de) | Nukleosidderivative in kombinationspräparaten zur behandlung von hsv krankheiten | |
| EP0990441A4 (en) | MEDICINES FOR TREATING DIABETIC NEPHROSIS | |
| FI952170A7 (fi) | Koagulaatiota edistävää aktiivista ainetta sisältävä stabiili valmisteveren koagulaatiosairauksien hoitamiseksi | |
| DK0653939T3 (da) | Anvendelse af en Hymenoptera-gift til fremstilling af et medikament til behandling af DNA-virusinfektioner | |
| PT1214091E (pt) | Terapias para a insuficiencia renal cronica utilizando um ou mais antaginistas de integrina | |
| FR2764389B1 (fr) | Utilisation de venin de crotalus viridis helleri, procede et necessaire pour la determination de la reactivite de la proteine c activee |